SEC Company Response from Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Sep 6, 2019
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Sept. 6, 2019 · CIK: 0001541157 · Accession: 0001144204-19-043710
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233048
Letter
Akari Therapeutics, PLC
75/76 Wimpole Street
London W1G 9RT
United Kingdom
September 6, 2019
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Akari Therapeutics, PLC
Registration Statement on Form F-1
File No. 333-233048
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-233048) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on September 6, 2019 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.
Very truly yours,
AKARI THERAPEUTICS, PLC
Show Raw Text
CORRESP
1
filename1.htm
Akari Therapeutics, PLC
75/76 Wimpole Street
London W1G 9RT
United Kingdom
September 6, 2019
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Akari Therapeutics, PLC
Registration Statement on Form F-1
File No. 333-233048
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness
of the Registration Statement on Form F-1 (File No. 333-233048) of the Registrant (the “Registration Statement”)
be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on September 6, 2019 or as soon thereafter as
may be practicable.
The undersigned respectfully requests that
it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery
LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request
for acceleration.
Very truly yours,
AKARI THERAPEUTICS, PLC
By:
/s/ Dov Elefant
Name: Dov Elefant
Title: Chief Financial Officer